Drug Trial Radar · NCT07008469
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
199
Planned (sponsor's estimate)
Start
Jun 26, 2025
Primary completion
Oct 2030
Study completion Oct 2030
Sponsor
- Lead sponsor
- Avidity Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1
Conditions
- Myotonic Dystrophy Type 1
- DM1
- Myotonic Dystrophy
- Myotonia
- Myotonic Dystrophy 1
- Myotonic Disorders
- Steinert Myotonic Dystrophy
- Steinert Disease
Interventions
Del-desiran (AOC 1001)Drug
Del-desiran will be administered by intravenous (IV) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- TEAEsTime frame: From enrollment to the end of treatment at 4 years
Locations
35 sites in 10 countries. Site status is shown where the registry gives one.
University of California, Los Angeles (UCLA)
Los Angeles, California
Stanford University
Stanford, California
University of Colorado
Denver, Colorado
University of Florida
Gainesville, Florida
University Research Center of South Florida
Tampa, Florida
Indiana University (IU)
Indianapolis, Indiana
Kansas University Medical Center
Kansas City, Kansas
Kennedy Krieger Institute
Baltimore, Maryland
Beth Israel Deaconess Medical Center
Boston, Massachusetts
University of Minnesota
Minneapolis, Minnesota
University of Rochester Medical Center
Rochester, New York
Duke University Medical Center
Durham, North Carolina
Wake Forest
Winston-Salem, North Carolina
University of Cincinnati Gardner Neuroscience Institute
Cincinnati, Ohio
Ohio State University
Columbus, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
Houston Methodist Neurological Institute
Houston, Texas
Virginia Commonwealth University
Richmond, Virginia
University of Washington
Seattle, Washington
The Ottawa Hospital
Ottawa, Ontario, Canada
Montreal Neurological Institute
Montreal, Quebec, Canada
Aarhus University Hospital
Aarhus, Denmark
Rigshospitalet
Copenhagen, Denmark
AP-HP Hopital Pitie-Salpetriere
Paris, France
Klinikum der Ludwig-Maximilians-Universitaet Muenchen
München, Germany
Fondazione Serena Onlus - Centro Clinico NeMO Milano
Milan, Italy
National Hospital Organization Osaka Toneyama Medical Center
Osaka, Japan
Osaka University Hospital
Osaka, Japan
National Center of Neurology and Psychiatry
Tokyo, Japan
Aomori Hospital
Aomori, Aomori, Japan
Maastricht University Medical Center
Maastricht, Netherlands
Stichting Radboud Universitair Medisch Centrum
Nijmegen, Netherlands
Hospital Universitario Donostia
San Sebastián, Spain
University College London Hospital
London, United Kingdom
St. Georges University Hospitals NHS Foundation Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.